Latest news about Parmax Pharma
Parmax Pharma
136.40
+1.35(+1.00%)
Company Performance:
View Company Insights1D+1.00%
1M+11.35%
6M+395.10%
1Y+302.36%
5Y0.00%
More news about Parmax Pharma
25Jun 26
Parmax Pharma publishes corrigendum to EGM notice
Parmax Pharma has issued a corrigendum to its EGM notice dated June 8, 2026, correcting the category of Ms. Sheetal Hiren Doshi from 'Promoter' to 'Promoter Group' and fixing a broken hyperlink for the Practicing Company Secretary's certificate. The EGM is scheduled for July 2, 2026, via Video Conferencing. The total warrants offered are 21,45,145 for a consideration of ₹7,82,97,793.
23Jun 26
Pradeep Gosalia sells 8.02% stake in Parmax Pharma
Pradeep Gosalia has disposed of 3,00,000 equity shares in Parmax Pharma Ltd, reducing his holding from 8.09% to 0.07%. The transaction was executed via a share purchase agreement on June 18, 2026.
23Jun 26
Parmax Pharma open offer at ₹42.80 per share for 26% stake
Acquirers Dhiren Chandulal Shah and Sunil Chinubhai Shah have launched a mandatory open offer to acquire up to 26% of Parmax Pharma Limited at ₹42.80 per share, aggregating to ₹10.04 crore. The offer follows a share purchase agreement and preferential issue that will trigger a change of control. The tendering period runs from July 30 to August 12, 2026, with Fedex Securities Private Limited acting as the manager to the offer.
19Jun 26
Parmax Pharma stake rises to 27.20% after share acquisition
Abhay Chinubhai Shah acquired 2,49,394 shares, representing a 2.76% stake in Parmax Pharma Limited, on June 18, 2026. The shares were purchased via an off-market transaction at ₹35.00 per share. Following this acquisition, the total shareholding of the acquirers and Persons Acting in Concert (PACs) increased to 27.20%.
15Jun 26
Parmax Pharma open offer at ₹42.80 per share for 26% stake
Dhiren Chandulal Shah and Sunil Chinubhai Shah have announced an open offer to acquire up to 26% of the expanded voting share capital of Parmax Pharma Limited at ₹42.80 per share, aggregating to ₹10.04 crore. The offer is triggered by a share purchase agreement dated June 08, 2026, to acquire shares from existing promoters and a proposed preferential issue of equity shares and warrants. Upon completion, the existing promoters will exit, and the acquirers will assume control, with no intention to delist the shares.
09Jun 26
Parmax Pharma EGM set for July 2 to approve ₹19.28 crore preferential issue
Parmax Pharma has scheduled an EGM on July 2, 2026, to approve raising ₹19.28 crore via preferential allotment of equity shares and warrants to 14 allottees. The issue, priced at ₹36.50 per share, includes a change in control and requires increasing authorised share capital to ₹10 crore.
03Jun 26
Parmax Pharma FY26 net loss widens to ₹4.16 crore
Parmax Pharma Limited reported a widened net loss of ₹4.16 crore for FY26, driven by a decline in revenue to ₹12.12 crore and a sharp rise in finance costs to ₹12.40 crore. The Board approved the audited results on June 03, 2026, with statutory auditors issuing an unmodified opinion. Operational highlights include no depreciation charged on specific plants and an insurance claim provision of ₹3.5 crore.
31May 26
Parmax Pharma EGM passes three resolutions, rejects two
Parmax Pharma Limited conducted an Extra Ordinary General Meeting on May 27, 2026, approving the re-appointment of Umang Alkesh Gosalia as Managing Director and the appointments of Pradeep Ramniklal Gosalia and Salma Badrudin Thobhani as Non-Executive Directors. The resolutions to appoint Ashish Atmaram Shah and Anjana Paresh Shah as Independent Directors were not passed. A total of 2,345,178 votes were polled, with the promoter group fully supporting all resolutions.
02May 26
Parmax Pharma Re-appoints Dr. Umang Gosalia as Managing Director for Five Years
Parmax Pharma Limited's Board of Directors approved the re-appointment of Dr. Umang Gosalia as Managing Director for five years from June 28, 2026 to June 27, 2031, subject to shareholder approval. Dr. Gosalia, who holds a Ph.D. in Organic Chemistry and has been with the company since 2016, currently oversees all production activities and brings over 15 years of chemistry experience to the role.
17Apr 26
Parmax Pharma Limited Files SEBI Compliance Certificate for Q4 FY26 Dematerialization Process
Parmax Pharma Limited filed its Q4 FY26 compliance certificate under SEBI Regulation 74(5) on April 17, 2026, confirming proper dematerialization procedures during the quarter ended March 31, 2026. The company dematerialized 200 shares for shareholder Ketan R Jani through two certificates processed on January 23, 2026. Registrar Purva Sharegistry (India) Pvt. Ltd. provided confirmation of compliance with prescribed timelines and verification procedures.
25Mar 26
Parmax Pharma Limited Appoints Ms. Bhakti Aghera as Company Secretary and Compliance Officer
Parmax Pharma Limited has appointed Ms. Bhakti Aghera as Company Secretary and Compliance Officer effective March 25, 2026. The Board of Directors approved the appointment based on the Nomination and Remuneration Committee's recommendation. Ms. Aghera is an ICSI associate member with six years of corporate legal and secretarial experience and has previously worked with the company.
15Feb 26
Parmax Pharma Reports Q3 FY26 Net Loss of Rs 73.19 Lakh, Revenue Drops 31.2% YoY
Parmax Pharma Limited announced deteriorating Q3 FY26 results with net loss widening to Rs 73.19 lakh from Rs 39.45 lakh year-on-year, while revenue dropped 31.2% to Rs 432.57 lakh. Nine-month performance showed even steeper declines with 62.4% revenue drop and losses mounting to Rs 357.48 lakh. The Board of Directors approved these unaudited results on February 14, 2026, ensuring regulatory compliance under SEBI regulations.
17Nov 25
Parmax Pharma Reports Significant Loss of Rs 284.29 Crore for H1 2025
Parmax Pharma Limited reported significant financial losses for the half-year ended September 30, 2025. Despite a 21.25% increase in revenue to Rs 447.32 crore, the company's net loss widened by 40.69% to Rs 284.29 crore. Total expenses surged by 28.01% to Rs 732.97 crore, outpacing revenue growth. The basic EPS declined to -Rs 7.60 from -Rs 5.40 in the previous year. Auditors noted pending insurance claims and non-provision of depreciation on certain assets.
05Sept 25
Parmax Pharma Reports Mixed Financial Results for FY 2023 with Revenue Decline
Parmax Pharma Limited's FY 2023 results show a decline in performance. Annual revenue decreased to Rs 154,243.45 thousand from Rs 182,511.20 thousand in FY 2022. The company reported a net loss of Rs 1,040.68 thousand, compared to a profit of Rs 1,415.13 thousand in the previous year. Quarterly revenue for Q4 2023 was Rs 63,819.33 thousand, down from Rs 70,879.78 thousand in Q4 2022. However, the company posted a quarterly net profit of Rs 1,729.60 thousand. Total assets stood at Rs 176,126.31 thousand as of March 31, 2023. The statutory auditors issued an unmodified opinion on the financial results.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Zydus Life Science
Cipla
Laurus Labs
Mankind Pharma
Dr Reddys Laboratories
Aurobindo Pharma
Lupin
1,868.90
(+1.72%)
9,410.50
(+0.38%)
4,970.00
(+2.69%)
1,161.00
(+0.09%)
1,386.10
(-0.60%)
2,017.50
(+3.25%)
2,437.80
(+5.96%)
1,198.30
(+1.12%)
1,713.40
(-1.19%)
2,124.50
(+1.99%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
